The Impact of Chronic E-Cigarette Usage on Microvascular Health

April 2, 2026 updated by: Virginia Commonwealth University
The study is focused on investigating the mechanisms involved in microvascular health in subjects that use e-cigarettes frequently. To explore microvascular health, different techniques and compounds. For one of the tests, iontophoresis, the drug's use will be stored and handled as described by the approved IND and non-IDS plan.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Electronic cigarettes or e-cigarettes have become increasingly popular, due to their promotion as a healthy alternative to traditional tobacco cigarettes. However, there are large discrepancies of knowledge in understanding how these e-cigarettes affect the subjects health and the way their body uses oxygen. The overall goal of this study is to evaluate e-cigarettes usage on subjects health.

Study Type

Observational

Enrollment (Estimated)

44

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • United States
    • Virginia
      • Richmond, Virginia, United States, 23298
        • Recruiting
        • Virginia Commonwealth University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Chronic e-cigs users and never users that are between 18 and 29 years of age.

Description

e-Cig users arm

Inclusion Criteria:

  • Between 18 and 29 years of age
  • Used e-cigarettes with nicotine (≥3 times/week for ≥6 months)

Exclusion Criteria:

  • 17 years old and younger or 30 years old or older.
  • Former combustible tobacco user/ former smoker
  • Use of cigarettes for 15 days or more in the past 60 days
  • Use of other tobacco products (cigars, hookah, smokeless), marijuana and/or illicit or prescription drugs weekly or more frequently in the past 60 days
  • Evidence of cardiovascular, pulmonary, renal, hepatic, metabolic, cerebral diseases or sleep disorders
  • Disorder or use of medication that affects cardiopulmonary health
  • Evidence of pregnancy or current nursing

Non e-Cig using arm

Inclusion

- Between 18 and 29 years of age

Exclusion

  • 17 years old and younger or 30 years old and older
  • Use of cigarettes or other tobacco products more than 50 times in their lifetime.
  • Evidence of cardiovascular, pulmonary, renal, hepatic, metabolic, cerebral diseases or sleep disorders
  • Disorder or use of medication that affects cardiopulmonary health
  • Evidence of pregnancy or current nursing

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Chronic e-cigs users
Used e-cigarettes with nicotine (≥3 times/week for ≥6 months)
Other: E-cig use
Based on e-cigarette usage, participants will be divided into those who used e-cigarettes and those who did not use e-cigarettes
Never Users
Use of cigarettes or other tobacco products less than 50 times in their lifetime.
Other: E-cig use
Based on e-cigarette usage, participants will be divided into those who used e-cigarettes and those who did not use e-cigarettes

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Endothelial dependent dilation
Time Frame: Participation is one week
Endothelial-dependent dilation will be assessed using laser doppler speckle contrast in both groups through the intervention
Participation is one week
Neurogenic response
Time Frame: Participation is one week
Neurogenic response will be assessed using axon reflex in both groups through the intervention
Participation is one week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Virginia Commonwealth University

Investigators

  • Principal Investigator: Paula Rodriguez Miguelez, Virginia Commonwealth University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 14, 2023

Primary Completion (Estimated)

April 28, 2026

Study Completion (Estimated)

April 28, 2026

Study Registration Dates

First Submitted

February 24, 2025

First Submitted That Met QC Criteria

February 28, 2025

First Posted (Actual)

March 6, 2025

Study Record Updates

Last Update Posted (Actual)

April 3, 2026

Last Update Submitted That Met QC Criteria

April 2, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • HM20029023

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on E-Cig Use

Clinical Trials on E-cig use

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe